Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gareth J. Morgan is active.

Publication


Featured researches published by Gareth J. Morgan.


British Journal of Haematology | 2003

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Robert A. Kyle; J. Anthony Child; Kenneth C. Anderson; Bart Barlogie; Régis Bataille; William Bensinger; Joan Bladé; Mario Boccadoro; William S. Dalton; Meletios A. Dimopoulos; Benjamin Djulbegovic; Mark Drayson; Brian G. M. Durie; Thiery Facon; Rafael Fonseca; Gösta Gahrton; Philip R. Greipp; Jean Luc Harousseau; David P. Harrington; Mohamad A. Hussein; Douglas E. Joshua; Heinz Ludwig; Gareth J. Morgan; Martin M. Oken; R. Powles; Paul G. Richardson; David Roodman; Jesús F. San Miguel; Kazuyuki Shimizu; Chaim Shustik

Summary. The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is <u200a30u2003g/l and the bone marrow clonal cells <u200a10% with no evidence of multiple myeloma, other B‐cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M‐protein is ≥u200a30u2003g/l and/or bone marrow clonal cells ≥u200a10% but no related organ or tissue impairment (ROTI)(end‐organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTI. Non‐secretory myeloma is characterized by the absence of an M‐protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (±u2003recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma.


Archive | 2001

Development of Diagnostic Criteria and Identification of Prognostic Factors

Roger G. Owen; Sharon Barrans; Stephen J. Richards; J. Anthony Child; L. A. Parapia; Gareth J. Morgan; Andrew Jack


Archive | 2013

increased risk of acute leukemia in adults Low NAD(P)H:quinone oxidoreductase 1 activity is associated with

Philippa L. Roddam; R. A. Cartwright; Gareth J. Morgan; Martyn T. Smith; Yunxia Wang; Eleanor Kane; Sara Rollinson; Joseph L. Wiemels; Eve Roman


Archive | 2013

nonmyeloablative stem cell transplantation In vivo CAMPATH-1H prevents graft-versus-host disease following

Stephen Mackinnon; Carmen Ruiz de Elvira; Catherine Williams; Stephen Devereux; David C. Linch; Stephen A. Schey; Premini Mahendra; Gareth J. Morgan; G Hale; Herman Waldmann; Stephen H. Robinson; Karl S. Peggs; Stephanie Verfuerth; Ruth Pettengell; D. Kottaridis; Donald Milligan; Rajesh Chopra; Ronjon Chakraverty


Archive | 2013

leukemia hydroxymethyltransferase genes and risk of adult acute lymphocytic Polymorphisms in the thymidylate synthase and serine

Sara Rollinson; Eve Roman; R. A. Cartwright; Gareth J. Morgan; Christine F. Skibola; Martyn T. Smith; Alan Hubbard; Barry Shane; Abby C. Roberts; Graham R. Law


Archive | 2013

the MRC Pilot Study safe and achieves a high percentage of molecular responses. Results of Autografting for younger patients with chronic lymphocytic leukaemia is

Christopher McConkey; David Cunningham; Gareth J. Morgan; D. Catovsky; Donald Milligan; Savio Fernandes; Ranjit Dasgupta; Estella Matutes; Christopher D


Archive | 2010

germinal center B cells immunoglobulin heavy chain switch mu region indicates an origin from Follicular lymphoma with a novel t(14;18) breakpoint involving the

Gareth J. Morgan; Carel J. M. van Noesel; Philip M. Kluin; James A. L. Fenton; Jan-Willem Vaandrager; Wilhelmina M. Aarts; Richard J. Bende; K. J. Heering


Archive | 2010

myeloid leukemia following chemotherapy predicts treatment outcome and risk of acute XPD Genetic variation in

David Swirsky; Gareth J. Morgan; Christopher P. Wild; James M. Allan; Alex Smith; Keith Wheatley; Robert Kerrin Hills; Lois B. Travis; Deirdre A. Hill


Archive | 2005

Poster sessions. Identification of collaborating oncogeneic events leading to disease progression in myeloma cases with a t(4;14) and t(11;14) using SNP and gene expression arrays

Matthew W. Jenner; Brian A. Walker; Paola E. Leone; David Gonzalez; Fiona M. Ross; Cheng Li; Faith E. Davies; Gareth J. Morgan


Archive | 2004

(927) Follow up Analysis for MRC Myeloma VII Trial. Session Type: Poster Session 81-I

Gareth J. Morgan; Faith E. Davies; Kim Hawkins; Sue E. Bell; Julia M. Nowlin Brown; Roger G. Owen

Collaboration


Dive into the Gareth J. Morgan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew Jack

Leeds Teaching Hospitals NHS Trust

View shared research outputs
Top Co-Authors

Avatar

David Gonzalez

Leeds Teaching Hospitals NHS Trust

View shared research outputs
Top Co-Authors

Avatar

Donald Milligan

Heart of England NHS Foundation Trust

View shared research outputs
Researchain Logo
Decentralizing Knowledge